Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?

Zhuan Jiang and Lillian Barra
The Journal of Rheumatology May 2025, jrheum.2025-0423; DOI: https://doi.org/10.3899/jrheum.2025-0423
Zhuan Jiang
Z. Jiang, MD, Department of Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhuan Jiang
Lillian Barra
L. Barra, MD, MPH, Department of Medicine, Division of Rheumatology, Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lillian Barra
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Giant cell arteritis (GCA) is a large-vessel vasculitis that affects individuals over the age of 50 and predominantly women in their 70s.1 The estimated pooled incidence of GCA is approximately 10 per 100,000 persons aged 50 years or older, with a higher incidence of 20-25 per 100,000 seen in Scandinavian countries and other northern countries, including Canada.2-4

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 52, Issue 6
1 Jun 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
Zhuan Jiang, Lillian Barra
The Journal of Rheumatology May 2025, jrheum.2025-0423; DOI: 10.3899/jrheum.2025-0423

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
Zhuan Jiang, Lillian Barra
The Journal of Rheumatology May 2025, jrheum.2025-0423; DOI: 10.3899/jrheum.2025-0423
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Reversing the Tide of the Growing Burden of Avoidable Musculoskeletal Pain and Disability
  • Interferon Response Gene Score in Juvenile Dermatomyositis
  • Revisiting Magnetic Resonance Imaging Structural Lesions in the Sacroiliac Joints
Show more Editorials

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire